KOREA WHO

Jin Yang-gon is the Chairman and CEO of HLB.

He also serves as an executive director of HLB Life Science, a subsidiary company.

He is working on the commercialization of new drugs in the HLB Group, including the anticancer drug 'Rivoceranib,' while also securing new growth engines through mergers and acquisitions.

He was born on January 14, 1966, in Busan. He attended middle and high school in Jeonju, Jeollabuk-do.

He graduated from Wonkwang University with a degree in law and received a master's degree in business administration from Yonsei University Graduate School.

He worked at Busan Bank and later at Peace Bank.

During the IMF financial crisis, he mistakenly co-signed a guarantee, leading to his early retirement and opening a beer hall, which he did not manage to keep running for long and eventually closed down.

After establishing the consulting firm J&Lee Partners, he successfully consulted for a small machinery parts company, gaining a good reputation and expanding his business.

He entered the field of mergers and acquisitions by establishing an investment company, and started the bio business by acquiring HLB.

He is applying for approval for Rivoceranib as a first-line treatment for liver cancer and preparing for its commercialization.

He is not good at harsh words and emphasizes people-centered management. He considers the late Chung Ju-yung, the honorary chairman of the Hyundai Group, as his role model.

#HLB #JinYanggon #Rivoceranib #anticancerdrug #biotechnology #mergersandacquisitions #peoplecenteredmanagement #WonkwangUniversity #YonseiUniversity #ChungJuyung